Explanipedia

Biomarker-driven therapeutic strategies in advanced gastric cancer: a case series of curative responses Open

Daniel Park, Lu Pu, Mengni Guo, Won Jin Jeon, Esther G Chong , et al. · 2025

These cases highlight the transformative impact of biomarker-driven therapy in advanced GC. The integration of programmed cell death ligand 1 (PD-L1) inhibitors and HER2-targeted agents alongside chemotherapy can enable curative-intent sur…

Prediction of Loss of Reduction in Unstable Colles’ Fractures following Supplementary Percutaneous K-wire Pinning Open

Chung-Tsen Hsueh, Ching-Hou Ma, Yuan‐Kun Tu, I‐Ming Jou, Chin‐Hsien Wu · 2025

Background: Colles’ fractures are one of the most common types of injury treated by an orthopedic surgeon. With a rapid increase in elderly populations, supplementary percutaneous K-wire pinning may not be able to maintain fracture reducti…

Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors Open

Young Kwang Chae, Megan Othus, Sandip Pravin Patel, Benjamin Powers, Chung-Tsen Hsueh , et al. · 2024

Background Dual inhibition using anti-programmed death-1 (PD-1) and anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) checkpoint inhibitors has proven effective in many cancers. However, its efficacy in rare solid cancers remains unclear. Des…

Perspectives on the Potential Curability of Metastatic Gastric Cancer: Insights from Biomarker-Driven Approaches Open

Lu Pu, Daniel Park, Won Jin Jeon, Mengni Guo, Farris Al-Manaseer , et al. · 2024

A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for locally advanced pancreatic cancer Open

Samrat M. Sanghvi, Alex Coffman, Chung-Tsen Hsueh, Joseph I. Kang, Annie Park , et al. · 2022

ClinicalTrials.gov identifier (NCTNCT01683422).

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) Open

Michael J. Wagner, Megan Othus, Sandip Pravin Patel, Chris Ryan, Ashish Sangal , et al. · 2021

Purpose Angiosarcoma is a rare aggressive endothelial cell cancer with high mortality. Isolated reports suggest immune checkpoint inhibition efficacy in angiosarcoma, but no prospective studies have been published. We report results for an…

Proton stereotactic body radiation therapy for liver metastases—results of 5-year experience for 81 hepatic lesions Open

Alex Coffman, Daniel C. Sufficool, Joseph I. Kang, Chung-Tsen Hsueh, Sasha Swenson , et al. · 2021

Proton SBRT for the treatment of liver metastases has promising LC rates with the ability to safely treat multiple liver metastases. Accrual continues for our phase II trial treating liver metastases with Proton SBRT to 60 GyE (Gray equiva…

Anthracycline-induced cardiotoxicity: A case report and review of literature Open

Esther G Chong, Eric H. Lee, Reena Sail, Laura Denham, Gayathri Nagaraj , et al. · 2021

We present a case of 35-year-old African American female developing cardiogenic shock shortly after receiving a cumulative dose of 450 mg/m² doxorubicin over 9 mo. Cardiac monitoring and management of patients receiving anthracy…

795 A multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) Open

Michael Wagner, Megan Othus, Sandip Pravin Patel, Christopher Ryan, Ashish Sangal , et al. · 2020

Background Angiosarcoma is a rare cancer of endothelial cells that can be aggressive and carries a high mortality. A subset of angiosarcomas are characterized by high tumor mutational burden (TMB) and UV light exposure DNA mutational signa…

Targeted and novel therapy in advanced gastric cancer Open

Julie H. Selim, Shagufta Shaheen, Wei-Chun Sheu, Chung-Tsen Hsueh · 2019

The systemic treatment options for advanced gastric cancer (GC) have evolved rapidly in recent years. We have reviewed the recent data of clinical trial incorporating targeted agents, including inhibitors of angiogenesis, human epidermal g…

Concomitant KRAS and BRAF mutations in colorectal cancer Open

Lauren Midthun, Shagufta Shaheen, Jeremy Deisch, Maheswari Senthil, James Tsai , et al. · 2019

BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAP-kinase signaling pathway. While previously considered mutually exclusive, concomitant mutations in both KRAS and BRAF genes have been identified in colo…

Sustained complete response to erlotinib in squamous cell carcinoma of the head and neck: A case report Open

Mie Mie Thinn, Chung-Tzu Hsueh, Chung-Tsen Hsueh · 2019

We report a case of metastatic SCCHN achieving durable complete response from erlotinib. Patient experienced skin rash and diarrhea toxicities which were likely predictors of his treatment response.

Thyroid dysfunction from inhibitor of fibroblast growth factor receptor Open

Jeffrey Ahn, Justin T. Moyers, John Wong, Chung-Tsen Hsueh · 2019

The role of bile acids in cellular invasiveness of gastric cancer Open

Yu-Chung Wu, Chang‐Fang Chiu, Chung-Tzu Hsueh, Chung-Tsen Hsueh · 2018

Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature Open

Shagufta Shaheen, Hamid Mirshahidi, Gayathri Nagaraj, Chung-Tsen Hsueh · 2018

With increasing use of immune checkpoint inhibitors, clinicians need to be aware of the unusual immune-related adverse events in order to provide timely management and effective patient care. To our knowledge, this is the first reported ca…

A phase I trial of Proton stereotactic body radiation therapy for liver metastases Open

Joseph I. Kang, Daniel C. Sufficool, Chung-Tsen Hsueh, Andrew Wroe, B Patyal , et al. · 2018

Biologically ablative Proton SBRT doses are well tolerated in patients with limited liver metastases with no patients experiencing any grade 2+ acute toxicity. Results from this trial provide the grounds for an ongoing phase II Proton SBRT…

Metastatic squamous cell carcinoma of colon from esophageal cancer Open

Natasha Garg, Constance Stoehr, Yan Zhao, Heather Rojas, Chung-Tsen Hsueh · 2017

Colonic metastasis from esophageal SCC is rare, and associated with poor prognosis. There are no definite features in terms of location, histological differentiation etc. that contribute to colonic metastasis from primary esophageal SCC. T…

Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study Open

John Sarantopoulos, Alain C. Mita, Aiwu Ruth He, James L. Wade, Chung-Tsen Hsueh , et al. · 2017

Mild-moderate HI did not cause substantial decline in cabazitaxel clearance. Cabazitaxel dose reductions in patients with mild-moderate HI, and a contraindication in patients with severe HI, are justified based on safety data.

Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma Open

Chung-Tzu Hsueh, Julie H. Selim, James Tsai, Chung-Tsen Hsueh · 2016

Liposome, albumin and polymer polyethylene glycol are nanovector formulations successfully developed for anti-cancer drug delivery. There are significant differences in pharmacokinetics, efficacy and toxicity between pre- and post-nanovect…

Chung-Tsen Hsueh YOU? Author Swipe